Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: a Phase ll Randomised Trial

NCT03875573 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT03875573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03875573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: a Phase ll Randomised Trial
Lead sponsor
Jules Bordet Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 6, 2019
Completion date
September 30, 2029
Enrollment
147 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

luminal b